cyrilzakka/clinical-trials huggingface dataset:
Multimodal Imaging-assisted Diagnosis Model for Cervical Spine Tumors

Cervical spine tumor is a small sample of tumor disease with low incidence, great harm, and complex anatomical structure. It is very difficult to identify and classify benign and malignant cervical spine tumors clinically.

The deep learning model we constructed in the early stage has a higher accuracy rate for the image diagnosis of cervical spondylosis with a large number of cases, and a better clinical application effect, but the accuracy rate for cervical spine tumors with a small number of cases is lower. The reason may be the amount of data. With limited tasks, the traditional deep learning model is difficult to play an effective role.

Based on this, we propose to build a small sample-oriented deep learning model to assist clinicians in the diagnosis of cervical spine tumors with multimodal images, and to evaluate the benign and malignant tumors.

Cervical spine tumor is a small-sample tumor disease with low incidence, great harm, and complex anatomical structure. It is very difficult to identify and classify benign and malignant cervical spine tumors clinically. The deep learning model we constructed in the early stage is suitable for the large number of cases. The imaging diagnosis of cervical spondylosis has a high accuracy rate and a good clinical application effect, but the accuracy rate is low for cervical spine tumors with a small number of cases. The reason may be that for tasks with limited amount of data, the traditional deep learning model is difficult to play an effective role. Based on this, we propose to construct a small sample-oriented deep learning model to assist clinicians in the diagnosis of cervical spine tumors in multi-modal imaging, and to evaluate the benign and malignant tumors. This research will not only improve the efficiency and efficiency of cervical spine tumor imaging diagnosis. Accuracy, to guide clinical personalized treatment, will also provide a basis for the clinical application of deep learning in the field of small samples, which has important clinical significance.

Eligibility Criteria:
Inclusion Criteria:

* 18-50 years old, about 300 males and females; in the orthopedics outpatient and emergency department of our hospital, the imaging scans (X-ray, CT, MR) showed no obvious abnormalities.

Exclusion Criteria:

* have had surgery before acquiring the images, Those who have cervical spine fractures, deformities, infections, etc. who cannot cooperate with imaging examinations, and those who have not signed the informed consent. The normal control group" includes about 600 patients with normal or slightly degenerated cervical spine, as a standard for training computers to recognize cervical spine structures Images and control images for detecting tumor lesions.
Partnership-Project - Reinforcing Partnership Between Cancer Patient, General Practitioner and Oncologist During Chemotherapy

Background International guidelines underline the importance of strengthening the coordination and continuity of cancer care. The different roles of general practitioners and oncologists with regard to treatment, follow-up and rehabilitation during and after cancer treatment are often obscure to cancer patients. Parallel courses of healthcare are often taking place instead of coordinated care characterized by continuity and partnership between care providers. Patients may feel uncertain about the health professionals' skills and area of responsibility. Healthcare seeking and support during and after cancer treatment may, therefore, be inappropriate, leaving patients feeling insecure and lost between care providers.The study aims to design and evaluate a new way of communication and shared decision-making that brings the patient, the oncologist and general practitioner together in a shared video-consultation in the early phase of chemotherapeutic treatment. The effect of the intervention in addition to usual care will be tested in a randomized controlled trial at Vejle Hospital in the Region of Southern Denmark. Based on sample size calculation, investigators intent to include 300 patients at the Department of Oncology and their general practitioners. Results and process outcomes will be evaluated qualitatively and quantitatively, questionnaires to patients, general practitioners and oncologists, and data from registers.


Eligibility Criteria:
Inclusion Criteria:

* Newly referred cancer patient scheduled for chemotherapy at the Department for Oncology, Vejle Hospital, Region of Southern Denmark
* Aged 18 years and over
* Able to speak and read Danish
* Mentally able to cooperate
* Listed with a general practitioner (98 % of the danish population)
* Written and verbal informed consent given

Exclusion Criteria:

* none
Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise

The aim of the current study is to investigate the therapeutic effect and especially the mode of action of Wobenzym® plus, an anti-inflammatory drug containing proteolytic enzymes, on exercise induced muscle damage (eiMD) and recovery time in male amateur sportsmen with medium proficiency level compared to placebo.


Eligibility Criteria:
Inclusion Criteria:

* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
* Subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry, haematology
* Not anticipating any planned changes in lifestyle regarding activity and nutrition for the duration of the study
* Non smoker
* Men with strength training experience
* Age: 20-50 years
* BMI ≥20 kg/m2 and ≤ 32 kg/m2
* medium concentric strength ability (150-300 Nm)

Exclusion Criteria:

* Relevant history or presence of any medical disorder, potentially interfering with this trial (e.g. volunteers having experienced any cardiovascular events such as infarction, angina, surgical endocoronary intervention, stroke or volunteers suffering from diabetes as well as acute or chronic injury of the musculoskeletal system, e.g. cruciate ligament rupture.
* No intake of anti-inflammatory medication/ food supplements or intake of medications that directly affect parameters of muscle function or performance within 4 weeks prior to visit 1 or during the trial
* Subjects not willing to abstain from intake of analgesic medication 24 hours prior to and during visit 1 and 2.
* For this trial clinically relevant abnormal laboratory, vital signs or physical findings at screening
* Known hypersensitivity to the study preparation or to single ingredients (e.g. Lactose intolerance)
* Drug, alcohol and/or medication abuse
* Known HIV-infection
* Known acute or chronic hepatitis B and C infection
* Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
* Blood donation within 4 weeks prior to trial start (visit 1) or during trial.
Anterior Mandibular Region for Immediate Implant Placement

Immediate implant placement has been proven to be a successful treatment modality, it is however considered a technique sensitive procedure, which mandates careful planning on basis of the recommended guidelines and thorough site assessment. The anatomical characteristics play a major role in the treatment planning, to determine that enough alveolar bone housing is available to accommodate the implant in the correct prosthetic-driven position and to avoid complications that may be caused by injury of the adjacent anatomical structures. There is scarcity in the literature regarding data on the anatomical features of the mandibular anterior zone in relevance to immediate implant planning. Analysis of the anatomical landmarks of the mandibular anterior region to determine the thickness of the labial and lingual alveolar bony plates, in addition to the bony socket configuration along with the labio-lingual socket dimension and relate them to immediate implant treatment planning


Eligibility Criteria:
Inclusion Criteria:

* CBCTs of teeth including the mandibular anterior zone showing central and lateral incisors and canines.

Exclusion Criteria:

* Radiographs of patients with malaligned teeth or with current or previous orthodontic treatment.
* Radiographs of patients with extensive bone loss due to infection or neoplasm in the area of interest
Carer Involvement in Exercises for People With Acquired Brain Injury.

Increasing the amount of exercises completed has been shown to help recovery for people after a brain injury. This study will explore if providing extra training of exercises prescribed to a patient and carer team, will allow more practice of these exercises, better abilities to move and balance, and to assess if carer confidence changes with doing this. It is a repeated case design in the in-patient acute Neurosciences setting at the Norfolk and Norwich University Hospital NHS Trust (NNUH).


Eligibility Criteria:
Inclusion

* Adults with acquired brain injury on NNUH Neurosciences Unit with a carer physically able to complete exercises with the patient.
* Patient to be able to follow simple commands (1 stage) for exercise intervention.
* Patient able to consent along with their relative together to participation in the study.

Exclusion:

* Discharge plan for ESD from initial assessment with no care package required due to too short timeframe of being an acute in-patient.
* Patient's with severe cognitive - communication deficits meaning they cannot follow 1 stage command for exercises or consent to the study.
* Severe pain, joint abnormality or spasticity limiting participation in exercise programme.
* Carer/relative not able to physically help the patient with the required exercises or carer/relative not able to consent to the study.
Investigation of Female Reproductive Hormone Dynamics During Adolescence

Irregular menstrual cycles are common in girls for several years after their first menstrual period. The cause of abnormal menstrual cycles during this time is not well-understood. The purpose of this study is to: 1) monitor girls during a menstrual cycle (with blood and urine sampling and serial pelvic ultrasounds) to identify those girls who do not ovulate (release of an egg from the ovary), and 2) determine whether cycles can be corrected by treating girls with a short course of low-dose estrogen and progesterone.


Eligibility Criteria:
Inclusion Criteria:

* no more than 3 ½ years postmenarchal

Exclusion Criteria:

* Subjects currently on or previously treated with medications that may affect reproductive hormones (eg birth control pills).
* Subjects with severe acne or hirsutism
* Subjects who exercise excessively (running \> 20 miles/week or its equivalent)
* Subjects with any of the following medical conditions: diabetes, hypertension, hyperlipidemia, valvular heart disease, lupus, rheumatoid arthritis, migraine headaches with aura, undiagnosed breast mass, inflammatory bowel disease, gallbladder disease, sickle cell disease, or thrombophilia.
* Current smoker
* History of deep venous thrombosis or pulmonary embolism in subject or first-degree relative
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.


Eligibility Criteria:
Inclusion Criteria:

* Previous stroke or TIA

Exclusion Criteria:

* coronary heart disease
Allergy Testing of Soldiers Prepared for International Mission

The goal of this prospective mono centric study is to identify relevant commercially available allergen extracts for allergy testing in soldiers prepared for international mission.

Participants will receive a skin prick test with the skin prick automated test device including 22 allergens and 2 controls on both forearms.


Eligibility Criteria:
Inclusion Criteria:

* Adult military personnel (18-65y) will be included. Soldiers with and without previous exposure to allergens in the regions of interest will be included. Soldiers who are performing desk tasks and not selected for international missions will serve as controls.

Exclusion Criteria:

* Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment
* Use of antihistaminic medication \< 7 days before the start of the study
* Use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study
* Use of topical corticoids on the forearm \< 7 days before the start of the study
* Use of Omalizumab \< 6 months before the start of the study
* Pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery).
Use of the Bra as Prevention of Sternal Wound Dehiscence in Cardiac Surgery

The aim of the study was to assess the efficacy of bra application as a prevention of dehiscence in women with median sternotomy.

Background: it is known that the size and support of the breasts are a specific problem in post-operative women of cardiac surgery by means of medium sternotomy. There is little evidence of the therapeutic action of the bra as a measure to prevent dehiscence of the surgical wound.

Aim: To assess the efficacy of bra application as a prevention of dehiscence in women with median sternotomy.

Methods: Randomised clinical trial; post-test control group in women undergoing cardiac surgery by mean sternotomy. Groups: application of post-surgical or non-surgical breast bra. Endpoint: incidence of dehiscence. Other variables: sociodemographic, signs of infection, pain, related to assessment of the wound on admission. Assessment of the surgical wound daily, at discharge, at month, 3 months and 6 months post discharge.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years
* Cardiac surgery intervention in the Germans Trias i Pujol University Hospital with non-critical preoperative
* Surgical intervention performed throughout medium sternotomy

Exclusion Criteria:

* More than 72 hours admitted in an intensive care unit after surgery
* Cognitive impairment or severe physical disability
* Mastectomy
* External wound occlusion with Opsite® fixative absorbent dressing
* Emergency surgery
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD). This study examines the safety and efficacy of combination therapy by imidapril (ACEI) or cilnidipine (CCB) in ADPKD patients whose blood pressure is not controlled under 120/80 mmHg by candesartan (ARB) alone.

Maximum dosage of candesartan is 8 mg/day. Dosage of imidapril is in the range of 2.5-10 mg/day. Dosage of cilnidipine is in the range of 5-20mg/day.

Eligibility Criteria:
Inclusion Criteria:

* ADPKD patients
* Blood pressure measured at out-patient setting is above 120/80 mmHg
* Age between 20 and 60 years old
* eGFR more than 30 ml/min/1.73m2
* Patients give informed consent

Exclusion Criteria:

* Patients with severe cardiovascular and hepatic disorders
* Patients with complications of central nervous vascular disorders
* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods
* Patients currently engaging in other experimental protocol
* Patients with intracranial aneurysma
* Patients who must use diuretics
* Allergic patients to Candesartan or Cilnidipine
* Patients whose hypertension is not controlled by medication of this protocol
Peripartum Anesthetic Management of Patients With Preeclampsia

The investigators will conduct a prospective, observational multicentral international study of perioperative management of patients with preeclampsia. The data will be collected from the maternity files and information systems of the medical centers including obstetric, anesthetic and neonatal parameters according to the attached Excel data table.

Results of the study will help to improve the management of patients with preeclampsia and will help to understand the nature and rate of complications. In addition, the study will help in comparing collected data to the data in the literature and as a result improve the safety of care and service that these patient receive in the institution.

In recent years, there has been a growing interest in anesthetic management of parturients diagnosed with preeclampsia.

The management of patients with preeclampsia is influenced by maternal conditions that include airway changes, coagulation dysfunction and significant hemodynamic changes.

Without changing regular practice the investigators will observe and collect data about: the type of anesthesia during surgery, perioperative monitoring and management of these patients (please see study outcomes). Complications reported in the literature include significant elevated blood pressure during laryngoscopy and development of intracranial hemorrhage, spinal/epidural bleeding during neuraxial anesthesia in patients with preeclampsia, and coagulation abnormalities.

Although the number of patients diagnosed with preeclampsia is estimated at five to ten percent of the general maternity population, there is a lack of prospective studies regarding the anesthetic management, obstetric complications and neonatal outcomes. In most centers the data regarding the rate of general anesthesia for cesarean section, the difficulty in performing neuraxial anesthesia, complications related to coagulation dysfunction and other complications, is limited.

In studies published by gynecologists or neonatologists, there is a significant lack of data relevant to the daily practice of anesthesiologists.

Eligibility Criteria:
Inclusion Criteria:

* Parturient with diagnosis of preeclampsia for Cesarean Section

Exclusion Criteria:

* No
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.

LHRH-a=Luteinizing Hormone-Releasing Hormone Analogues

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven diagnosis of prostate cancer
* Evidence of PSA progression despite castrate levels of testosterone (\<50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRH-a)
* Patients with non-metastatic or stable metastatic disease
* Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) \[cut off levels will be \> 20 U/L for enzyme linked immunosorbent (ELISA) assay and \> 100 ng/ml for immunoradiometric (IRMA) assay\]

Exclusion Criteria:

* Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel)
* First line treatment with antiandrogen in monotherapy
* Visceral metastasis
* Previous or concomitant treatment with a somatostatin analogue
How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

The study will seek to determine whether there is a corresponding deficit in school performance for teenagers with NF1. Secondly, the study seeks to explore the issue of self-esteem in teenagers with NF1.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Neurofibromatosis Type 1

Exclusion Criteria:

* Neurofibromatosis Type 2
* Schwannomatosis
The Effects of Metreleptin in Congenital Leptin Deficiency

This study has been designed to 1) provide access to metreleptin to the only two individuals in the US known to have congenital leptin deficiency (CLD) and 2) explore a variety of unanswered questions about leptin physiology in general and metreleptin therapy in CLD specifically.

The primary study endpoints include the following measures: body composition, measures of hepatic steatosis, measures of insulin sensitivity, and measures of sleep architecture.

Secondary study endpoints include assessment of clock gene expression, body temperature, thyroid function, gonadal function, cognitive function, eating behavior, physical activity, mood, quality of life, and body image.

Congenital leptin deficiency (CLD) is a rare autosomal recessive condition caused by a mutation in the leptin gene (LEP). This mutation leads to a severe deficiency in leptin, a hormone secreted primarily by adipocytes. Leptin is also secreted by gastric mucosal cells, in response to stimuli such as food intake. Leptin has many important physiologic roles, including serving as a signal to the hypothalamus of both long-term (adipocyte) and short-term (gastric) energy storage. Individuals with CLD have hyperphagia and morbid obesity with an onset in early childhood. Hypogonadotropic hypogonadism, insulin resistance, and immune dysfunction are also often observed in patients with CLD but these features can be of varying degrees of severity.

Recombinant human leptin (metreleptin; Myalept®) was approved by the U.S. Food and Drug Administration in 2014 to treat the complications of leptin deficiency in patients with generalized lipodystrophy (GL). Commercial use of metreleptin is restricted to patients with leptin deficiency due to GL. However, \~3 dozen patients worldwide who are known to have congenital leptin deficiency (CLD) have been treated safely and successfully with metreleptin in the investigational setting for two decades. Metreleptin therapy has been shown to reduce hunger and desire to eat in leptin-deficient humans, and significant weight loss is typical.

Some questions remain regarding the pluripotent effects of metreleptin in patients with CLD. Understudied aspects of physiology in these patients include the role of leptin (independent of weight) in insulin sensitivity, hepatic steatosis, and sleep. For each of these areas, there is preliminary evidence from humans or the ob/ob (leptin-deficient) mouse model for a beneficial role of leptin, but important knowledge gaps remain.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of congenital leptin deficiency
* Age 18 years or older
* Must agree to use contraception for the duration of treatment with metreleptin and for 6 months post-treatment completion.

Exclusion Criteria:

* Presence of a clinically significant medical condition that could significantly affect the risk/benefit ratio for metreleptin treatment, as judged by the PI
* Known allergies to E. coli-derived proteins or hypersensitivity to any component of metreleptin treatment